BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34230878)

  • 1. Molecular characterisation of
    Kloppers JF; de Kock A; Cronjé J; van Marle AC
    Afr J Lab Med; 2021; 10(1):1363. PubMed ID: 34230878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations.
    Gajendra S; Gupta R; Thakral D; Gupta SK; Jain G; Bakhshi S; Sharma A; Sahoo RK; Kumar L; Rai S; Singh S; Upadhyay AD
    Int J Lab Hematol; 2023 Apr; 45(2):221-228. PubMed ID: 36504282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary report.
    Helbig G; Wozniczka K; Wieclawek A; Soja A; Bartkowska-Chrobok A; Kyrcz-Krzemien S
    Contemp Oncol (Pozn); 2014; 18(4):241-5. PubMed ID: 25258581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia.
    Mahmood R; Altaf C; Malik HS; Khan SA
    Pak J Med Sci; 2019; 35(1):23-28. PubMed ID: 30881390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1749-1755. PubMed ID: 31244296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort.
    Marshall RC; Tlagadi A; Bronze M; Kana V; Naidoo S; Wiggill TM; Carmona SC
    Int J Lab Hematol; 2014 Dec; 36(6):656-64. PubMed ID: 24666762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India.
    Bhattacharyya J; Nath S; Saikia KK; Saxena R; Sazawal S; Barman MP; Kumar D
    Indian J Hematol Blood Transfus; 2018 Jan; 34(1):32-42. PubMed ID: 29398797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of a rapid and easy method for simultaneous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia].
    Lu Y; Wang Q; Mu QT; Yu MX; Huang Q; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):163-6. PubMed ID: 22487825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
    Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective.
    Sazawal S; Singh N; Jain S; Chhikara S; Chaubey R; Bhattacharyya J; Saikia KK; Mahapatra M; Saxena R
    Indian J Pathol Microbiol; 2017; 60(3):355-359. PubMed ID: 28937371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile.
    Cabrera ME; Monardes V; Salgado C; Cares C; Gonzalez C
    Hematol Transfus Cell Ther; 2023; 45(1):77-82. PubMed ID: 34690101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.